[ CAS No. 117106-20-4 ] {[proInfo.proName]}

Name: 117106-20-4|(2S,3R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-(tert-butoxy)butanoic acid|95%
Brand: Ambeed
SKU: A254623
Price: 21.0 USD
Availability: InStock
Rating: 90 (22 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

DV 2D 3D

3d Animation Molecule Structure of 117106-20-4

Structure of 117106-20-4 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 117106-20-4 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 117106-20-4 ]

SDS Specification

Alternatived Products of [ 117106-20-4 ]

Product Details of [ 117106-20-4 ]

CAS No. :	117106-20-4	MDL No. :	MFCD02094431
Formula :	C₂₄H₂₉NO₅	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	VIUVLZHFMIFLHU-VFNWGFHPSA-N
M.W :	411.49	Pubchem ID :	7010372
Synonyms :

Calculated chemistry of [ 117106-20-4 ]

Physicochemical Properties

Num. heavy atoms :	30
Num. arom. heavy atoms :	12
Fraction Csp3 :	0.42
Num. rotatable bonds :	9
Num. H-bond acceptors :	5.0
Num. H-bond donors :	1.0
Molar Refractivity :	115.23
TPSA :	76.07 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	Yes
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	Yes
Log Kp (skin permeation) :	-5.87 cm/s

Lipophilicity

Log Po/w (iLOGP) :	3.33
Log Po/w (XLOGP3) :	4.14
Log Po/w (WLOGP) :	4.52
Log Po/w (MLOGP) :	2.83
Log Po/w (SILICOS-IT) :	3.56
Consensus Log Po/w :	3.68

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-4.7
Solubility :	0.00818 mg/ml ; 0.0000199 mol/l
Class :	Moderately soluble
Log S (Ali) :	-5.44
Solubility :	0.00148 mg/ml ; 0.00000359 mol/l
Class :	Moderately soluble
Log S (SILICOS-IT) :	-5.49
Solubility :	0.00132 mg/ml ; 0.00000321 mol/l
Class :	Moderately soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	3.0
Synthetic accessibility :	4.61

Safety of [ 117106-20-4 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P261-P305+P351+P338	UN#:	N/A
Hazard Statements:	H302-H315-H319-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 117106-20-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 117106-20-4 ]
Downstream synthetic route of [ 117106-20-4 ]

[ 117106-20-4 ] Synthesis Path-Upstream 1~1

1
[ 42417-72-1 ]
[ 28920-43-6 ]
[ 117106-20-4 ]

Reference： [1] Tetrahedron, 1988, vol. 44, # 6, p. 1773 - 1782

[ 117106-20-4 ] Synthesis Path-Downstream 1~32

1
[ 42417-72-1 ]
[ 28920-43-6 ]
[ 117106-20-4 ]

Reference： [1]Tetrahedron,1988,vol. 44,p. 1773 - 1782

2
[ 117106-20-4 ]
[ 117106-26-0 ]
[ 116236-49-8 ]

Reference： [1]Tetrahedron,1988,vol. 44,p. 1773 - 1782

3
[ 108-24-7 ]
[ 71989-35-0 ]
[ 132327-80-1 ]
[ 117106-20-4 ]
[ 143824-78-6 ]
H-V-OWang resinFmoc-I-OH [ No CAS ]
AcTQI(MeT)WV-OH [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2002,vol. 12,p. 2471 - 2474

4
[ 71989-31-6 ]
[ 108-24-7 ]
[ 117106-20-4 ]
[ 144120-54-7 ]
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(4(bis(dimethylamino)phosphoryloxy)phenyl)propanoic acid [ No CAS ]
Fmoc-Leu-OH [ No CAS ]
Ac-Tyr(PO₃H₂)-Leu-Pro-Gln-N-MeThr-NH₂ [ No CAS ]

Reference： [1]Journal of Medicinal Chemistry,2005,vol. 48,p. 6661 - 6670

5
[ 2592-95-2 ]
[ 117106-20-4 ]
C₃₀H₃₂N₄O₅ [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2011,vol. 76,p. 6686 - 6693

6
[ 117106-20-4 ]
C₂₄H₂₈ClNO₄ [ No CAS ]

Reference： [1]Journal of Organic Chemistry,2011,vol. 76,p. 6686 - 6693

7
[ 35661-39-3 ]
Me<SUB>2</SUB>Val-HIV-OH [ No CAS ]
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
[ 53267-93-9 ]
[ 103478-62-2 ]
[ 84000-07-7 ]
[ 117106-20-4 ]
[ 138775-22-1 ]
C₈₀H₁₂₂N₁₀O₁₉ [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2015,vol. 137,p. 13488 - 13491

8
[ 35661-39-3 ]
Me<SUB>2</SUB>Val-HIV-OH [ No CAS ]
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-methoxypropanoic acid [ No CAS ]
[ 53267-93-9 ]
[ 103478-62-2 ]
[ 117106-20-4 ]
(2R)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}propanoic acid [ No CAS ]
[ 138775-22-1 ]
C₈₀H₁₂₂N₁₀O₁₉ [ No CAS ]

Reference： [1]Journal of the American Chemical Society,2015,vol. 137,p. 13488 - 13491

9
[ 117106-20-4 ]
N-Fmoc-N-methyl-L-threonine [ No CAS ]

Reference： [1]European Journal of Organic Chemistry,2015,vol. 2015,p. 7043 - 7052

10
methyl (5S,8S,11S,14S,17S,20R,23S,26S,29S)-29-amino-5-[(1R)-1-hydroxyethyl]-8-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-14,17,26-triisobutyl-11-isopropyl-3,9,12,18,20,23,27,31-octamethyl-4,7,10,13,16,19,22,25,28-nonaoxo-3,6,9,12,15,18,21,24,27-nonaazadotriacontan-1-oate [ No CAS ]
[ 117106-20-4 ]
methyl (5S,8S,11S,14S,17R,20S,23S,26S,29S,32S)-5-((1R)-1-tert-butoxyethyl)-1-(9H-fluoren-9-yl)-32-[(1R)-1-hydroxyethyl]-29-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-8,11,20,23-tetraisobutyl-26-isopropyl-4,10,14,17,19,25,28,34-octamethyl-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-2-oxa-4,7,10,13,16,19,22,25,28,31,34-undecaazahexatriacontan-36-oate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
1.58 g	With 1-hydroxy-7-aza-benzotriazole; N-(3-dimethylaminopropyl)-N-ethylcarbodiimide; In dichloromethane; at 20℃; for 5h;Cooling with ice;	Prep.95 To a solution of the object compound of Prep.166 below (1.20 g), (2S,3R)-3-tert-butoxy-2-([(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}butanoic acid (527 mg), and HOAt (174 mg) in CH2Cl2 (20 ml) was added a solution of WSCD (199 mg) in CH2Cl2 (1 ml) under ice-bath cooling. After being stirred at the same temperature for 1 hr and at room temperature for 4 hrs, the reaction solution was concentrated in vacuo. The residue was dissolved in AcOEt (50 ml) and the solution was washed with 0.5N HCl, 1M NaHCO3, and brine, dried over MgSO4, and concentrated in vacuo. The resulting residue was purified by Silica-gel column (eluent: 2% MeOH in CHCl3) to give methyl (5S,8S,11S,14S,17R,20S,23S,26S,29S,32S)-5-(1-tert-butoxyethyl)-1-(9H-fluoren-9-yl)-32-[(1R)-1-hydroxyethyl]-29-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-8,11,20,23-tetraisobutyl-26-isopropyl-4,10,14,17,19,25,28,34-octamethyl-3,6,9,12,15,18,21,24,27,30,33-undecaoxo-2-oxa-4,7,10,13,16,19,22,25,28,31,34-undecaazahexatriacontan-36-oate (1.58 g) as an amorphous powder.

Reference： [1]Patent: EP1957518,2015,B1 .Location in patent: Paragraph 0117

11
methyl (2S,5S,8S,11S,14S,17R,20S,23S,26S)-26-amino-2-[(1R)-1-hydroxyethyl]-5-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-11,14,23-triisobutyl-8-isopropyl-6,9,15,17,20,24,28-heptamethyl-4,7,10,13,16,19,22,25-octaoxo-3,6,9,12,15,18,21,24-octaazanonacosan-1-oate [ No CAS ]
[ 117106-20-4 ]
methyl (5S,8S,11S,14S,17R,20S,23S,26S,29S,32S)-5-((1R)-1-tert-butoxyethyl)-1-(9H-fluoren-9-yl)-32-[(1R)-1-hydroxyethyl]-29-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-8,11,20,23-tetraisobutyl-26-isopropyl-4,10,14,17,19,25,28-heptamethyl-3,6,9,12,15,18,21,24,27,30-decaoxo-2-oxa-4,7,10,13,16,19,22,25,28,31-decaazatritriacontan-33-oate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
1.6 g	With 1-hydroxy-7-aza-benzotriazole; N-(3-dimethylaminopropyl)-N-ethylcarbodiimide; In dichloromethane; at 20℃; for 5h;Cooling with ice;	Prep.93 To a solution of the object compound of Prep.3 (1.20 g), <strong>[117106-20-4](2S,3R)-3-tert-butoxy-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}butanoic acid</strong> (516 mg), and HOAt (171 mg) in CH2Cl2 (20 ml) was added a solution of WSCD (195 mg) in CH2Cl2 (1 ml) under ice-bath cooling. After being stirred at the same temperature for 1 hr and at room temperature for 4 hrs, the reaction solution was concentrated in vacuo. The residue was dissolved in AcOEt (50 ml) and the solution was washed with 0.5N HCl, 1M NaHCO3, and brine, dried over MgSO4, and concentrated in vacuo to give methyl (5S,8S,11S,14S,17R,20S,23S,26S,29S,32S)-5-(1-tert-butoxyethyl)-1-(9H-fluoren-9-yl)-32-[(1R)-1-hydroxyethyl]-29-[(1R,2R,4E)-1-hydroxy-2-methyl-4-hexen-1-yl]-8,11,20,23-tetraisobutyl-26-isopropyl-4,10,14,17,19,25,28-heptamethyl-3,6,9,12,15,18,21,24,27,30-decaoxo-2-oxa-4,7,10,13,16,19,22,25,28,31-decaazatritriacontan-33-oate (1.6 g) as an amorphous powder.

Reference： [1]Patent: EP1957518,2015,B1 .Location in patent: Paragraph 0115

12
Fmoc-Pra-Wang resin [ No CAS ]
[ 35661-39-3 ]
[ 109425-55-0 ]
[ 117106-20-4 ]
C₄₂H₅₆N₅O₁₀Pol [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: Tetrapeptides 3a-d were synthesized by manual solid-phase peptide synthesis (SPPS) using 2-chlorotritylchloride polymer resin (2-CTC, 1.63mmol/g) in a 10-mL disposable syringe fitted with a porous polyethylene filter and N-terminal fluorenylmethyloxycarbonyl-protected amino acids. Coupling of the first amino acid: Fmoc-propargyl-Gly-OH (0.8 eq.) to the 2-CTC resin (1.0 eq.) was performed in anhydrous DCM (7.5mL) in the presence of DIEA (3.0 eq.) with shaking at room temperature for 2h. Then, MeOH (2mL) was added to cap the unreacted resin and the mixture was shaken for 30min. The resin was filtered, washed with several portions of DCM, DMF and again DCM and dried under high vacuum, overnight. Loading of the starting material was calculated via increase in dry weight. Next, the resin swelling was performed in DMF for 20min, Fmoc protecting group was removed by treatment with 20% piperidine in DMF (2×3mL, 5+20min) and the polymer was washed with DMF (5×3mL, 5×2min). Then, coupling of the appropriate amino acid: Fmoc-AA-OH (4.0 eq.) was performed in DMF (3mL) using HBTU (4.0 eq.), in the presence of DIEA (8.0 eq.) with shaking at room temperature. In the case of Fmoc-Ala-OH for 4h, with Fmoc-Orn(Boc)-OH, Fmoc-Thr (tBu)-OH and Fmoc-N-Me-Thr (tBu)-OH overnight and with Fmoc-Arg (Pbf)-OH and Fmoc-His (Trt)-OH the double coupling was performed (after 2h the resin was washed with DMF and treated with a freshly made solution of Fmoc-AA-OH, HBTU and DIEA in DMF and shaken for 2h). After each coupling, the resin was washed with DMF (4×4mL) and subsequently de-protected and washed as described above. At the end of the coupling cycle the resin was washed with several portions of DMF, MeOH and DCM and dried under high vacuum, overnight. Method (A) for coupling of the tail via HBTU activation: The coupling of the tails at the N-terminus of the synthesized tetrapeptides was performed using the acid (4 eq.) in DMF (2mL), in the presence of DIEA (8 eq.) and HBTU (4 eq.) at room temperature, shaking overnight. The resin was then washed extensively with several portions of DMF, MeOH and DCM and dried under high vacuum. Method (B) for coupling of the tail via mixed anhydride: Step 1. Heterocyclic acid derivative (0.52mmol, 1 eq.) was reacted with Boc anhydride (2.11mmol, 4 eq.) in dry tetrahydrofuran in presence of pyridine (2.64mmol, 5 eq.) at r. t. overnight. After full consumption of starting material volatiles were removed in vacuo. Aqueous 0.5M hydrochloric acid solution was added and the product was extracted with ethyl acetate. The organic layer was washed with water, separated and dried over sodium sulfate. Volatiles were removed in vacuo yielding a crude product as yellowish oil, which was used in the next step without further purification. Step 2. The 2-CTC resin containing 3a (0.13mmol, 1 eq.) was suspended in DMF (3mL) containing mixed anhydride prepared in Step 1 (presumed 0.52mmol, 4 eq.) and DIPEA (1.82mmol, 14 eq.). The reaction mixture was shaken at r. t. overnight. The resin was filtered, washed with DMF (5×2mL), DCM (5×2mL) and THF (5×4mL). General method for cleavage from the solid support. 2-CTC resin containing oligopeptides was added into a mixture of HFIP/DCM 1:4 (4mL) and the reaction mixture was shaken at room temperature for 1.5h. The resin was filtered off and washed with DCM and THF. The volatiles were evaporated in vacuo. Purification: The crude peptides were dissolved in THF (2.5mL) and H2O/MeCN (1:1, 2.5mL), filtered through a 0.45mum nylon membrane filter and purified in 1-3 runs by preparative RP-HPLC. The reported yields are based on calculated loading of the oligopeptide on 2-CTC resin.

Reference： [1]European Journal of Medicinal Chemistry,2018,vol. 157,p. 1346 - 1360

13
[ 68858-20-8 ]
[ 45170-31-8 ]
tert-butyl (S)-2-(((benzyloxy)carbonyl)(methyl)amino)-3-(4-methoxy-1-tosyl-1H-indol-3-yl)propanoate [ No CAS ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
Fmoc-N-methylvaline [ No CAS ]
[ 76-05-1 ]
[ 197458-39-2 ]
C₇₅H₁₁₉N₁₃O₁₆*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
5%	Stage #1: Fmoc-N-methylvaline With thionyl chloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Inert atmosphere; Stage #2: With piperidine In N,N-dimethyl-formamide Inert atmosphere; Stage #3: Fmoc-Val-OH; Boc-N-Me-Val-OH; tert-butyl (S)-2-(((benzyloxy)carbonyl)(methyl)amino)-3-(4-methoxy-1-tosyl-1H-indol-3-yl)propanoate; N-(9-fluorenylmethoxycarbonyl)-N-methyl-L-leucine; Fmoc-Thr-OH; (2S,3R)-3-tert-butoxy-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}butanoic acid; trifluoroacetic acid; Fmoc-threo-β-OH-L-Phe-OH Further stages;

Reference： [1]Hawkins, Paige M. E.; Tran, Wendy; Nagalingam, Gayathri; Cheung, Chen-Yi; Giltrap, Andrew M.; Cook, Gregory M.; Britton, Warwick J.; Payne, Richard J. [Chemistry - A European Journal, 2020, vol. 26, # 66, p. 15200 - 15205]

14
[ 68858-20-8 ]
tert-butyl (S)-2-(((benzyloxy)carbonyl)(methyl)amino)-3-(4-methoxy-1-tosyl-1H-indol-3-yl)propanoate [ No CAS ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
Fmoc-N-methylvaline [ No CAS ]
[ 76-05-1 ]
[ 138775-22-1 ]
[ 197458-39-2 ]
C₈₃H₁₃₄N₁₄O₁₇*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
2%	Stage #1: Fmoc-N-methylvaline With thionyl chloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Inert atmosphere; Stage #2: With piperidine In N,N-dimethyl-formamide Inert atmosphere; Stage #3: Fmoc-Val-OH; tert-butyl (S)-2-(((benzyloxy)carbonyl)(methyl)amino)-3-(4-methoxy-1-tosyl-1H-indol-3-yl)propanoate; N-(9-fluorenylmethoxycarbonyl)-N-methyl-L-leucine; Fmoc-Thr-OH; (2S,3R)-3-tert-butoxy-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}butanoic acid; trifluoroacetic acid; N-Fmoc-N-methyl-L-isoleucine; Fmoc-threo-β-OH-L-Phe-OH Further stages;

15
[ 68858-20-8 ]
tert-butyl (S)-2-(((benzyloxy)carbonyl)(methyl)amino)-3-(4-methoxy-1-tosyl-1H-indol-3-yl)propanoate [ No CAS ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
Fmoc-N-methylvaline [ No CAS ]
[ 76-05-1 ]
[ 138775-22-1 ]
(S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanoic acid [ No CAS ]
C₈₃H₁₃₄N₁₄O₁₆*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
3%	Stage #1: Fmoc-N-methylvaline With thionyl chloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Inert atmosphere; Stage #2: With piperidine In N,N-dimethyl-formamide Inert atmosphere; Stage #3: Fmoc-Val-OH; tert-butyl (S)-2-(((benzyloxy)carbonyl)(methyl)amino)-3-(4-methoxy-1-tosyl-1H-indol-3-yl)propanoate; N-Fmoc L-Phe; N-(9-fluorenylmethoxycarbonyl)-N-methyl-L-leucine; Fmoc-Thr-OH; (2S,3R)-3-tert-butoxy-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}butanoic acid; trifluoroacetic acid; N-Fmoc-N-methyl-L-isoleucine; (S)-2-((S)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanoic acid Further stages;

16
[ 68858-20-8 ]
[ 35661-60-0 ]
[ 71989-31-6 ]
[ 71989-14-5 ]
[ 86123-10-6 ]
[ 117106-20-4 ]
[ 150629-67-7 ]
1-tert-butoxycarbonyl-N-[(9-fluorenyl)methoxycarbonyl]-D-tryptophan [ No CAS ]
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
cyclo(-Leu-DTrp-Pro-(N-Me)Thr-Asp-Leu-DPhe-Lys(Dde)-Val-Arg-) [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
19.6%	Stage #1: Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 3h; Stage #2: With piperidine; 1,8-diazabicyclo[5.4.0]undec-7-ene In N,N-dimethyl-formamide for 0.5h; Stage #3: Fmoc-Val-OH; Fmoc-Leu-OH; Fmoc-Pro-OH; Fmoc-(tBu)Asp-OH; Fmoc-D-Phe-OH; (2S,3R)-3-tert-butoxy-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}butanoic acid; Fmoc-Lys(Dde)-OH; 1-tert-butoxycarbonyl-N-[(9-fluorenyl)methoxycarbonyl]-D-tryptophan Further stages;

Reference： [1]Sun, Haixia; Chen, Daoyuan; Zhan, Siyue; Wu, Weijian; Xu, Huiying; Luo, Chunxiang; Su, Hui; Feng, Yanqiao; Shao, Weiyan; Wan, Arabella; Zhou, Binhua; Wan, Guohui; Bu, Xianzhang [Journal of Medicinal Chemistry, 2020, vol. 63, # 19, p. 11286 - 11301]

17
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 84000-07-7 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₈₆H₁₃₉N₁₃O₁₉*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
89 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)propanoic acid; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

Reference： [1]Hawkins, Paige M. E.; Hoi, David M.; Cheung, Chen-Yi; Wang, Trixie; Quan, Diana; Sasi, Vishnu Mini; Liu, Dennis Y.; Linington, Roger G.; Jackson, Colin J.; Oehlers, Stefan H.; Cook, Gregory M.; Britton, Warwick J.; Clausen, Tim; Payne, Richard J. [Journal of Medicinal Chemistry, 2022, vol. 65, # 6, p. 4893 - 4908]

18
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 77128-70-2 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₈₅H₁₃₇N₁₃O₁₉*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
3.4 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; N-Fmoc-sarcosine; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

19
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 71989-31-6 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₈₇H₁₃₉N₁₃O₁₉*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
10.7 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; Fmoc-Pro-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

20
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
(2S,4R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-(tert-butoxy)pyrrolidine-2-carboxylic acid [ No CAS ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₉₁H₁₄₇N₁₃O₂₀*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
2.6 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; (2S,4R)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)-4-(tert-butoxy)pyrrolidine-2-carboxylic acid; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

21
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
(S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)piperidine-2-carboxylic acid [ No CAS ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₂HF₃O₂*C₈₈H₁₄₁N₁₃O₁₉ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
9.6 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; (S)-1-(((9H-fluoren-9-yl)methoxy)carbonyl)piperidine-2-carboxylic acid; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

22
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 77128-73-5 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₉₂H₁₄₃N₁₃O₁₉*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
14.9 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; (2S)-N-fluorenylmethyloxycarbonyl-2-amino-N-methyl-3-phenylpropanoic acid; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

23
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
[ 188970-92-5 ]
C₉₀H₁₄₄N₁₄O₂₁*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
6.8 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH; N-α-Fmoc-N-β-alloc-L-diaminopropionic acid Further stages;

24
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 71989-33-8 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₉₀H₁₄₇N₁₃O₂₀*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
10 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Ser(tBu)-OH; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

25
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 71989-14-5 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₉₁H₁₄₇N₁₃O₂₁*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
8 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-(tBu)Asp-OH; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

26
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
Fmoc-L-Chg-OH [ No CAS ]
C₉₁H₁₄₇N₁₃O₁₉*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
2.5 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH; Fmoc-L-Chg-OH Further stages;

27
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₈₈H₁₄₃N₁₃O₁₉*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
7.6 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

28
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₈₉H₁₄₅N₁₃O₁₉*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
7.2 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

29
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₉₉H₁₅₂N₁₄O₂₁*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
14.9 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

30
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 135112-28-6 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₈₈H₁₄₃N₁₃O₁₉*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
6 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; Fmoc L-norvaline; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

31
[ 67-56-1 ]
[ 68858-20-8 ]
[ 45170-31-8 ]
[ 35661-40-6 ]
[ 103478-62-2 ]
[ 73731-37-0 ]
[ 117106-20-4 ]
[ 77284-32-3 ]
[ 76-05-1 ]
[ 143824-78-6 ]
C₈₉H₁₄₅N₁₃O₁₉*C₂HF₃O₂ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
11 mg	Stage #1: N-Fmoc L-Phe With 2-chlorotrityl chloride resin; N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; for 16h; Stage #2: With piperidine In N,N-dimethyl-formamide at 20℃; for 16h; Stage #3: methanol; Fmoc-Val-OH; Boc-N-Me-Val-OH; (2S)-2-[(9H-fluoren-9-ylmethoxy)carbonyl](methyl)amino}-4-methylpentanoic acid; Fmoc-Thr-OH; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH; Fmoc-L-norleucine; trifluoroacetic acid; N^α-Fmoc-Trp(Nⁱⁿ-Boc)-OH Further stages;

32
benzyl(2-amino-2-(3-bromophenyl)ethyl)carbamate [ No CAS ]
[ 117106-20-4 ]
C₄₀H₄₄BrN₃O₆ [ No CAS ]
C₄₀H₄₄BrN₃O₆ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	Stage #1: benzyl(2-amino-2-(3-bromophenyl)ethyl)carbamate; Fmoc-N-Me-L-Thr(O<SUP>t</SUP>Bu)-OH With N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide at 0℃; for 0.5h; Stage #2: With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 0 - 25℃; for 3h;

Reference： [1]Cai, Zhengjun; Chen, Bingyi; Cheng, Bao; Gu, Qiong; Guo, Junsong; Luo, Zhiteng; Xu, Jun; Yu, Ying; Zhou, Huihao [Journal of Medicinal Chemistry, 2022, vol. 65, # 7, p. 5800 - 5820]

Same Skeleton Products

Related Products

Historical Records

Related Functional Groups of
[ 117106-20-4 ]

Amino Acid Derivatives

[ 201481-37-0 ]

Fmoc-Allo-Thr(tBu)-OH

Similarity: 0.95

[ 252049-06-2 ]

(2S,3R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-3-hydroxybutanoic acid

Similarity: 0.95

[ 138797-71-4 ]

(2R,3S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-(tert-butoxy)butanoic acid

Similarity: 0.95

[ 71989-35-0 ]

Fmoc-Thr(tBu)-OH

Similarity: 0.95

[ 122996-47-8 ]

(2S,4R)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)-4-(tert-butoxy)pyrrolidine-2-carboxylic acid

Similarity: 0.93

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}	{[ getRatePrice(item.pr_usd, 1,1) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]}	{[ item.pr_usastock ]}	Inquiry -	{[ item.pr_chinastock ]}	Inquiry -

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

[ CAS No. 117106-20-4 ] {[proInfo.proName]}

Quality Control of [ 117106-20-4 ]

Related Doc. of [ 117106-20-4 ]

Product Details of [ 117106-20-4 ]

Calculated chemistry of [ 117106-20-4 ]

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 117106-20-4 ]

Application In Synthesis of [ 117106-20-4 ]

[ 117106-20-4 ] Synthesis Path-Upstream 1~1

[ 117106-20-4 ] Synthesis Path-Downstream 1~32

Related Functional Groups of [ 117106-20-4 ]

Amino Acid Derivatives

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 117106-20-4 ]